Merit Medical (MMSI) Receives Upgrade to Buy: Implications for the Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 21 2025
0mins
Should l Buy MMSI?
Source: NASDAQ.COM
Merit Medical Upgrade: Merit Medical (MMSI) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Merit Medical, with the Zacks Consensus Estimate increasing by 0.1% over the past three months, suggesting an improvement in the company's underlying business.
Investment Opportunity: The upgrade places Merit Medical in the top 20% of Zacks-covered stocks, indicating potential for market-beating returns, making it an attractive investment opportunity for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MMSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MMSI
Wall Street analysts forecast MMSI stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 69.710
Low
90.00
Averages
104.63
High
122.00
Current: 69.710
Low
90.00
Averages
104.63
High
122.00
About MMSI
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merit Medical Systems Reports Strong Q4 2025 Earnings with Record Free Cash Flow
- Significant Revenue Growth: Merit Medical Systems reported total revenue of $393.9 million in Q4 2025, reflecting an 11% year-over-year increase, with U.S. sales up 12% and international sales up 6%, demonstrating strong performance across major markets and reinforcing its competitive position.
- Record Free Cash Flow: The company achieved a record free cash flow of $74 million in Q4, contributing to nearly $216 million for the full year 2025, indicating ongoing improvements in cash management and profitability that will support future investments and shareholder returns.
- Margin Expansion: The non-GAAP operating margin increased to 21% in Q4, up 138 basis points year-over-year, with a gross margin of 54.5%, marking the highest quarterly gross margin in the company's history, reflecting successful cost control and product mix optimization.
- Cautious 2026 Outlook: The company projects total GAAP net revenue growth of 6% to 8% for 2026, factoring in a 140 basis point headwind to revenue growth from the divestiture of the DualCap product line, as management remains vigilant about external challenges while maintaining confidence in growth prospects.
See More
Merit Medical Systems Q4 Earnings Exceed Expectations
- Strong Earnings Performance: Merit Medical Systems reported a Q4 non-GAAP EPS of $1.04, beating expectations by $0.09, which demonstrates the company's robust profitability in the medical device sector and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $393.9 million, reflecting a 10.9% year-over-year increase and surpassing market expectations by $2.98 million, indicating strong performance amid rising market demand and solidifying its market position.
- Optimistic Future Outlook: Merit Medical provided guidance for FY 2026 total revenue between $1.610 billion and $1.630 billion, representing a year-over-year growth of 6%-8%, with non-GAAP EPS projected between $4.01 and $4.15, showcasing sustained growth potential that attracts investor interest.
- Positive Stock Reaction: Following the earnings release, Merit Medical's shares rose by 2.3%, indicating market recognition of its financial performance and future prospects, which may further drive the company's expansion in the healthcare industry.
See More
Merit Medical Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Merit Medical Systems reported a net income of $38 million in Q4, translating to earnings of $0.63 per share, while adjusted earnings reached $1.04 per share, surpassing Wall Street's expectation of $0.96, indicating robust profitability.
- Solid Annual Results: For the full year, the company posted a profit of $128.5 million, or $2.13 per share, with total revenue of $1.52 billion, reflecting sustained growth and an increase in market share within the medical device sector.
- Optimistic Future Outlook: Merit Medical anticipates earnings per share in the range of $4.01 to $4.15 for 2023, with revenue projected between $1.61 billion and $1.63 billion, demonstrating confidence in future growth and positive market demand.
- Positive Market Reaction: The earnings beat is likely to boost investor confidence, potentially driving up the stock price and further solidifying the company's competitive position in the medical device industry.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, reflecting varying market perspectives on these companies' futures, which could influence investor decisions and market trends.
- Upgrades and Downgrades: Specific rating changes include both upgrades and downgrades for certain stocks, which may lead to short-term volatility in the respective stocks, prompting investors to pay close attention.
- Market Reaction Expectations: Analyst rating adjustments typically trigger immediate market reactions, as investors may reassess their portfolios based on this information, thereby impacting overall market sentiment.
- Further Information Access: For a complete view of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page to stay updated on the latest market dynamics and professional insights.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, analyst rating changes typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MMSI stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
See More
Wall Street's Latest Rating Changes Overview
- Amazon Downgrade: DA Davidson downgraded Amazon from Buy to Neutral, citing concerns that Amazon Web Services (AWS) is losing market share amid competition from Microsoft and Google, indicating a potential need for increased investment to regain its leading position in the cloud computing sector.
- Merit Medical Initiation: BTIG initiated coverage on Merit Medical with a Buy rating, highlighting its comprehensive product portfolio used across various interventional procedures, which underscores the company's high-quality positioning and growth potential in the medical device market.
- JBS Buy Rating: UBS initiated coverage on Brazilian meat company JBS with a Buy rating and a price target of $19.5 per share, implying a 23% upside, reflecting market confidence in its re-rating and potential stock price appreciation.
- Vistra Upgrade: Goldman Sachs upgraded Vistra from Neutral to Buy, projecting a potential EBITDA increase of 3-9% by 2028, indicating investor optimism regarding its future profitability and growth prospects in the nuclear energy sector.
See More
Merit Medical Systems Reports Strong Q4 2025 Earnings with Record Free Cash Flow
- Significant Revenue Growth: Merit Medical Systems reported total revenue of $393.9 million in Q4 2025, reflecting an 11% year-over-year increase, with U.S. sales up 12% and international sales up 6%, demonstrating strong performance across major markets and reinforcing its competitive position.
- Record Free Cash Flow: The company achieved a record free cash flow of $74 million in Q4, contributing to nearly $216 million for the full year 2025, indicating ongoing improvements in cash management and profitability that will support future investments and shareholder returns.
- Margin Expansion: The non-GAAP operating margin increased to 21% in Q4, up 138 basis points year-over-year, with a gross margin of 54.5%, marking the highest quarterly gross margin in the company's history, reflecting successful cost control and product mix optimization.
- Cautious 2026 Outlook: The company projects total GAAP net revenue growth of 6% to 8% for 2026, factoring in a 140 basis point headwind to revenue growth from the divestiture of the DualCap product line, as management remains vigilant about external challenges while maintaining confidence in growth prospects.
See More
Merit Medical Systems Q4 Earnings Exceed Expectations
- Strong Earnings Performance: Merit Medical Systems reported a Q4 non-GAAP EPS of $1.04, beating expectations by $0.09, which demonstrates the company's robust profitability in the medical device sector and boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $393.9 million, reflecting a 10.9% year-over-year increase and surpassing market expectations by $2.98 million, indicating strong performance amid rising market demand and solidifying its market position.
- Optimistic Future Outlook: Merit Medical provided guidance for FY 2026 total revenue between $1.610 billion and $1.630 billion, representing a year-over-year growth of 6%-8%, with non-GAAP EPS projected between $4.01 and $4.15, showcasing sustained growth potential that attracts investor interest.
- Positive Stock Reaction: Following the earnings release, Merit Medical's shares rose by 2.3%, indicating market recognition of its financial performance and future prospects, which may further drive the company's expansion in the healthcare industry.
See More
Merit Medical Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Performance: Merit Medical Systems reported a net income of $38 million in Q4, translating to earnings of $0.63 per share, while adjusted earnings reached $1.04 per share, surpassing Wall Street's expectation of $0.96, indicating robust profitability.
- Solid Annual Results: For the full year, the company posted a profit of $128.5 million, or $2.13 per share, with total revenue of $1.52 billion, reflecting sustained growth and an increase in market share within the medical device sector.
- Optimistic Future Outlook: Merit Medical anticipates earnings per share in the range of $4.01 to $4.15 for 2023, with revenue projected between $1.61 billion and $1.63 billion, demonstrating confidence in future growth and positive market demand.
- Positive Market Reaction: The earnings beat is likely to boost investor confidence, potentially driving up the stock price and further solidifying the company's competitive position in the medical device industry.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, reflecting varying market perspectives on these companies' futures, which could influence investor decisions and market trends.
- Upgrades and Downgrades: Specific rating changes include both upgrades and downgrades for certain stocks, which may lead to short-term volatility in the respective stocks, prompting investors to pay close attention.
- Market Reaction Expectations: Analyst rating adjustments typically trigger immediate market reactions, as investors may reassess their portfolios based on this information, thereby impacting overall market sentiment.
- Further Information Access: For a complete view of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page to stay updated on the latest market dynamics and professional insights.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, analyst rating changes typically influence investor decisions, potentially leading to price volatility in the affected stocks.
- Investor Focus: Investors considering purchasing MMSI stock should pay attention to analysts' opinions to make more informed investment decisions, especially amid increasing market uncertainty.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a comprehensive market perspective and data support.
See More
Wall Street's Latest Rating Changes Overview
- Amazon Downgrade: DA Davidson downgraded Amazon from Buy to Neutral, citing concerns that Amazon Web Services (AWS) is losing market share amid competition from Microsoft and Google, indicating a potential need for increased investment to regain its leading position in the cloud computing sector.
- Merit Medical Initiation: BTIG initiated coverage on Merit Medical with a Buy rating, highlighting its comprehensive product portfolio used across various interventional procedures, which underscores the company's high-quality positioning and growth potential in the medical device market.
- JBS Buy Rating: UBS initiated coverage on Brazilian meat company JBS with a Buy rating and a price target of $19.5 per share, implying a 23% upside, reflecting market confidence in its re-rating and potential stock price appreciation.
- Vistra Upgrade: Goldman Sachs upgraded Vistra from Neutral to Buy, projecting a potential EBITDA increase of 3-9% by 2028, indicating investor optimism regarding its future profitability and growth prospects in the nuclear energy sector.
See More
